| Journal | International journal of molecular sciences |
| Study Type | Clinical Study |
| Population | Human participants |
This item covers developments relevant to cannabis medicine and clinical practice. Clinicians monitoring evidence in this area should review the source material.
Melanoma is a malignant neoplasm that originates from melanocytes. It continues to pose a significant challenge in oncology due to its aggressive nature and limited treatment options. This study investigates the potential additive effects of PHEC-66, a cannabis extract, in combination with conventional chemotherapeutic agents auranofin, docetaxel, and cisplatin on the viability of a range of melanoma cell lines. These combinations were evaluated using the MTT assay on MM418-C1, MM329, C32, and D24 melanoma cells. There was a nuanced response observed when PHEC-66 was combined with docetaxel and auranofin in these cells, suggesting a potential additive effect. Contrastingly, the combination of PHEC-66 with cisplatin elicited an antagonistic effect, wherein the expected cytotoxicity of this drug was compromised. This unexpected interaction may stem from complex interplays between the agents that influence drug uptake, DNA damage response, and cell survival pathways. These findings unders
“This is a development worth tracking. The clinical implications will become clearer as more evidence accumulates.”
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
FAQ
This study item was assembled from normalized source metadata and pipeline scoring.
